These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21086021)

  • 61. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.
    Wood JP; Ellery PE; Maroney SA; Mast AE
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):169-76. PubMed ID: 24233490
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Factor Xa-inhibition in interventional cardiology].
    Ahrens I; Peter K; Bode C
    Hamostaseologie; 2007 Dec; 27(5):328-32. PubMed ID: 18060241
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.
    Gretler DD
    Clin Ther; 2003 Oct; 25(10):2564-74. PubMed ID: 14667957
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
    Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
    J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
    Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
    J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
    Becker RC; Yang H; Barrett Y; Mohan P; Wang J; Wallentin L; Alexander JH
    J Thromb Thrombolysis; 2011 Aug; 32(2):183-7. PubMed ID: 21516308
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
    Tóth O; Szabó C; Kecskés M; Pótó L; Nagy A; Losonczy H
    Life Sci; 2006 Jun; 79(4):317-23. PubMed ID: 16480745
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.
    Teng R; Butler K
    J Clin Pharm Ther; 2012 Dec; 37(6):704-11. PubMed ID: 22747575
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
    Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
    J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis during and after treatment with unfractionated heparin and enoxaparin].
    Averkov OV; Slavina NN; Dobrovol'skiĭ AB; Gratsianskiĭ NA
    Kardiologiia; 2003; 43(9):28-40. PubMed ID: 14593367
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Weight-Based Enoxaparin Achieves Adequate Anti-Xa Levels More Often in Trauma Patients: A Prospective Study.
    Stutsrim AE; Eady JM; Collum M; Rebo GJ; Rebo KA; Miller PR; Nunn AM
    Am Surg; 2021 Jan; 87(1):77-82. PubMed ID: 32915054
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
    Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
    Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
    Duschek N; Vafaie M; Skrinjar E; Hirsch K; Waldhör T; Hübl W; Bergmayr W; Knoebl P; Assadian A
    J Thromb Haemost; 2011 Nov; 9(11):2159-67. PubMed ID: 21910821
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS).
    Bertel O; Ramsay D; Wettstein T; Kurz DJ; Stettler I; Straumann E; Frielingsdorf J; Maurer D; Naegeli B
    EuroIntervention; 2010 Aug; 6(3):407-12. PubMed ID: 20884422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.